{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:03:38Z","timestamp":1785578618067,"version":"3.56.0"},"reference-count":39,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"9","funder":[{"DOI":"10.13039\/100006502","name":"Defense Sciences Office, DARPA","doi-asserted-by":"publisher","award":["W911NF-10-1-0378"],"award-info":[{"award-number":["W911NF-10-1-0378"]}],"id":[{"id":"10.13039\/100006502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2018,9,7]]},"abstract":"<jats:p>We present an adjuvant for intradermal use that works in humans, enabling self-administration in case of a flu pandemic.<\/jats:p>","DOI":"10.1126\/sciadv.aas9930","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T18:06:17Z","timestamp":1536775577000},"source":"Crossref","is-referenced-by-count":47,"title":["The adjuvant GLA-AF enhances human intradermal vaccine responses"],"prefix":"10.1126","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5901-3402","authenticated-orcid":true,"given":"Darrick","family":"Carter","sequence":"first","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."},{"name":"PAI Life Sciences Inc., Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"van Hoeven","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-9239","authenticated-orcid":true,"given":"Susan","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-2870","authenticated-orcid":true,"given":"Yotam","family":"Levin","sequence":"additional","affiliation":[{"name":"NanoPass Technologies Ltd., Nes Ziona, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2954-7232","authenticated-orcid":true,"given":"Efrat","family":"Kochba","sequence":"additional","affiliation":[{"name":"NanoPass Technologies Ltd., Nes Ziona, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Magill","sequence":"additional","affiliation":[{"name":"Defense Advanced Research Projects Agency, Arlington, VA 22203, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Charland","sequence":"additional","affiliation":[{"name":"Medicago, Qu\u00e9bec City, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-0484","authenticated-orcid":true,"given":"Nathalie","family":"Landry","sequence":"additional","affiliation":[{"name":"Medicago, Qu\u00e9bec City, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin","family":"Nu","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-2942","authenticated-orcid":true,"given":"Aude","family":"Frevol","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Ashman","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary K.","family":"Sagawa","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie","family":"Beckmann","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-100X","authenticated-orcid":true,"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Institute, Seattle, WA 98102, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4049\/jimmunol.1201060","article-title":"Toward animal cell culture-based influenza vaccine design: Viral hemagglutinin N-glycosylation markedly impacts immunogenicity","volume":"190","author":"H\u00fctter J.","year":"2013","unstructured":"J. H\u00fctter, J. V. R\u00f6dig, D. H\u00f6per, P. H. Seeberger, U. Reichl, E. Rapp, B. Lepenies, Toward animal cell culture-based influenza vaccine design: Viral hemagglutinin N-glycosylation markedly impacts immunogenicity. J. Immunol. 190, 220\u2013230 (2013).","journal-title":"J. Immunol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jbiotec.2012.10.005","article-title":"Effect of natural and chimeric haemagglutinin genes on influenza A virus replication in baby hamster kidney cells","volume":"162","author":"van Wielink R.","year":"2012","unstructured":"R. van Wielink, M. M. Harmsen, D. E. Martens, O. S. de Leeuw, B. P. H. Peeters, R. H. Wijffels, R. J. M. Moormann, Effect of natural and chimeric haemagglutinin genes on influenza A virus replication in baby hamster kidney cells. J. Biotechnol. 162, 197\u2013201 (2012).","journal-title":"J. Biotechnol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1016\/j.vaccine.2011.06.014","article-title":"Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines","volume":"29","author":"Khurana S.","year":"2011","unstructured":"S. Khurana, C. Larkin, S. Verma, M. B. Joshi, J. M. Fontana, A. C. Steven, L. R. King, J. Manischewitz, W. McCormick, R. K. Gupta, H. Golding, Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29, 5657\u20135665 (2011).","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.vaccine.2011.01.039","article-title":"Evaluation of the safety, reactogenicity and immunogenicity of FluBlok\u00ae trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50\u201364 years of age","volume":"29","author":"Baxter R.","year":"2011","unstructured":"R. Baxter, P. A. Patriarca, K. Ensor, R. Izikson, K. L. Goldenthal, M. M. Cox, Evaluation of the safety, reactogenicity and immunogenicity of FluBlok\u00ae trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50\u201364 years of age. Vaccine 29, 2272\u20132278 (2011).","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1467-7652.2008.00384.x","article-title":"Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice","volume":"6","author":"D\u2019Aoust M.-A.","year":"2008","unstructured":"M.-A. D\u2019Aoust, P.-O. Lavoie, M. M.-J. Couture, S. Tr\u00e9panier, J.-M. Guay, M. Dargis, S. Mongrand, N. Landry, B. J. Ward, L.-P. V\u00e9zina, Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 6, 930\u2013940 (2008).","journal-title":"Plant Biotechnol. J."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1750-2659.2011.00295.x","article-title":"A plant-based system for rapid production of influenza vaccine antigens","volume":"6","author":"Shoji Y.","year":"2012","unstructured":"Y. Shoji, C. E. Farrance, J. Bautista, H. Bi, K. Musiychuk, A. Horsey, H. Park, J. Jaje, B. J. Green, M. Shamloul, S. Sharma, J. A. Chichester, V. Mett, V. Yusibov, A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respi. Viruses 6, 204\u2013210 (2012).","journal-title":"Influenza Other Respi. Viruses"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"B. Chackerian J. T. Schiller Virus-like particles as antigen scaffolds in Vaccinology W. J. W. Morrow N. A. Sheikh C. S. Schmidt D. H. Davies Eds. (Wiley-Blackwell 2012) pp. 196\u2013208.","DOI":"10.1002\/9781118345313.ch13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","article-title":"The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza","volume":"8","author":"D\u2019Aoust M.-A.","year":"2010","unstructured":"M.-A. D\u2019Aoust, M. M.-J. Couture, N. Charland, S. Tr\u00e9panier, N. Landry, F. Ors, L.-P. V\u00e9zina, The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 8, 607\u2013619 (2010).","journal-title":"Plant Biotechnol. J."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"e15559","DOI":"10.1371\/journal.pone.0015559","article-title":"Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza","volume":"5","author":"Landry N.","year":"2010","unstructured":"N. Landry, B. J. Ward, S. Tr\u00e9panier, E. Montomoli, M. Dargis, G. Lapini, L.-P. V\u00e9zina, Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLOS ONE 5, e15559 (2010).","journal-title":"PLOS ONE"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clim.2016.03.008","article-title":"A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults","volume":"168","author":"Pillet S.","year":"2016","unstructured":"S. Pillet, \u00c9. Aubin, S. Tr\u00e9panier, D. Bussi\u00e8re, M. Dargis, J.-F. Poulin, B. Yassine-Diab, B. J. Ward, N. Landry, A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin. Immunol. 168, 72\u201387 (2016).","journal-title":"Clin. Immunol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1473-3099(16)00133-X","article-title":"Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: An exploratory, randomised, partly blinded trial","volume":"16","author":"Beals C. R.","year":"2016","unstructured":"C. R. Beals, R. A. Railkar, A. K. Schaeffer, Y. Levin, E. Kochba, B. K. Meyer, R. K. Evans, E. A. Sheldon, K. Lasseter, N. Lang, A. Weinberg, J. Canniff, M. J. Levin, Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: An exploratory, randomised, partly blinded trial. Lancet Infect. Dis. 16, 915\u2013922 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.vaccine.2016.03.016","article-title":"Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen","volume":"34","author":"Baldwin S. L.","year":"2016","unstructured":"S. L. Baldwin, W. Roeffen, S. K. Singh, R. W. Tiendrebeogo, M. Christiansen, E. Beebe, D. Carter, C. B. Fox, R. F. Howard, S. G. Reed, R. Sauerwein, M. Theisen, Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen. Vaccine 34, 2207\u20132215 (2016).","journal-title":"Vaccine"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"e41144","DOI":"10.1371\/journal.pone.0041144","article-title":"Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140","volume":"7","author":"Arias M. A.","year":"2012","unstructured":"M. A. Arias, G. A. Van Roey, J. S. Tregoning, M. Moutaftsi, R. N. Coler, H. P. Windish, S. G. Reed, D. Carter, R. J. Shattock, Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLOS ONE 7, e41144 (2012).","journal-title":"PLOS ONE"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002135"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/21645515.2015.1010871","article-title":"Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future","volume":"11","author":"Levin Y.","year":"2015","unstructured":"Y. Levin, E. Kochba, I. Hung, R. Kenney, Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Hum. Vaccin. Immunother. 11, 991\u2013997 (2015).","journal-title":"Hum. Vaccin. Immunother."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043540"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/17425247.2014.885947","article-title":"Cutaneous immunization: An evolving paradigm in influenza vaccines","volume":"11","author":"Gill H. S.","year":"2014","unstructured":"H. S. Gill, S.-M. Kang, F.-S. Quan, R. W. Compans, Cutaneous immunization: An evolving paradigm in influenza vaccines. Expert Opin. Drug Deliv. 11, 615\u2013627 (2014).","journal-title":"Expert Opin. Drug Deliv."},{"key":"e_1_3_2_19_2","unstructured":"J. Hickling R. Jones N. Nundy Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries (2010)."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1016\/j.vaccine.2016.09.008","article-title":"A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly","volume":"34","author":"Levin Y.","year":"2016","unstructured":"Y. Levin, E. Kochba, G. Shukarev, S. Rusch, G. Herrera-Taracena, P. van Damme, A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine 34, 5262\u20135272 (2016).","journal-title":"Vaccine"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.biopha.2016.08.026","article-title":"Transdermal delivery of vaccines\u2014Recent progress and critical issues","volume":"83","author":"Ita K.","year":"2016","unstructured":"K. Ita, Transdermal delivery of vaccines\u2014Recent progress and critical issues. Biomed. Pharmacother. 83, 1080\u20131088 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/COH.0b013e32833d2cdb","article-title":"Role of adjuvants in modeling the immune response","volume":"5","author":"Carter D.","year":"2010","unstructured":"D. Carter, S. G. Reed, Role of adjuvants in modeling the immune response. Curr. Opin. HIV AIDS 5, 409\u2013413 (2010).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"e_1_3_2_23_2","first-page":"e25","article-title":"Alum: An old dog with new tricks","volume":"5","author":"Wen Y.","year":"2016","unstructured":"Y. Wen, Y. Shi, Alum: An old dog with new tricks. Emerg. Microbes Infect. 5, e25 (2016).","journal-title":"Emerg. Microbes Infect."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2014.1004026"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/hv.4.5.6438","article-title":"Vaccine adjuvants: The dream becomes real","volume":"4","author":"Tagliabue A.","year":"2008","unstructured":"A. Tagliabue, R. Rappuoli, Vaccine adjuvants: The dream becomes real. Hum. Vaccin. 4, 347\u2013349 (2008).","journal-title":"Hum. Vaccin."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/13543776.2011.569494","article-title":"Toll-like receptor modulators: A patent review (2006\u20132010)","volume":"21","author":"Basith S.","year":"2011","unstructured":"S. Basith, B. Manavalan, G. Lee, S. G. Kim, S. Choi, Toll-like receptor modulators: A patent review (2006\u20132010). Expert Opin. Ther. Pat. 21, 927\u2013944 (2011).","journal-title":"Expert Opin. Ther. Pat."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09737"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1034\/j.1398-9995.2000.00501.x","article-title":"Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations","volume":"55","author":"Vogelbruch M.","year":"2000","unstructured":"M. Vogelbruch, B. Nuss, M. K\u00f6rner, A. Kapp, P. Kiehl, W. Bohm, Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 55, 883\u2013887 (2000).","journal-title":"Allergy"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"e63785","DOI":"10.1371\/journal.pone.0063785","article-title":"Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells","volume":"8","author":"Matthews K.","year":"2013","unstructured":"K. Matthews, N. P. Y. Chung, P. J. Klasse, M. Moutaftsi, D. Carter, A. M. Salazar, S. G. Reed, R. W. Sanders, J. P. Moore, Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PLOS ONE 8, e63785 (2013).","journal-title":"PLOS ONE"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10522-015-9576-x","article-title":"The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age","volume":"17","author":"Weinberger B.","year":"2016","unstructured":"B. Weinberger, C. Joos, S. G. Reed, R. Coler, B. Grubeck-Loebenstein, The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age. Biogerontology 17, 177\u2013187 (2016).","journal-title":"Biogerontology"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/infdis\/jir769","article-title":"GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults","volume":"205","author":"Behzad H.","year":"2012","unstructured":"H. Behzad, A. L. W. Huckriede, L. Haynes, B. Gentleman, K. Coyle, J. C. Wilschut, T. R. Kollmann, S. G. Reed, J. E. McElhaney, GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205, 466\u2013473 (2012).","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clim.2014.08.003","article-title":"Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens","volume":"154","author":"Landry N.","year":"2014","unstructured":"N. Landry, S. Pillet, D. Favre, J.-F. Poulin, S. Tr\u00e9panier, B. Yassine-Diab, B. J. Ward, Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin. Immunol. 154, 164\u2013177 (2014).","journal-title":"Clin. Immunol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"Santini-Oliveira M.","year":"2016","unstructured":"M. Santini-Oliveira, R. N. Coler, J. Parra, V. Veloso, L. Jayashankar, P. M. Pinto, M. A. Ciol, R. Bergquist, S. G. Reed, M. Tendler, Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine 34, 586\u2013594 (2016).","journal-title":"Vaccine"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: Safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler R. N.","year":"2015","unstructured":"R. N. Coler, M. S. Duthie, K. A. Hofmeyer, J. Guderian, L. Jayashankar, J. Vergara, T. Rolf, A. Misquith, J. D. Laurance, V. S. Raman, H. R. Bailor, N. D. Cauwelaert, S. J. Reed, A. Vallur, M. Favila, M. T. Orr, J. Ashman, P. Ghosh, D. Mondal, S. G. Reed, From mouse to man: Safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin. Trans. Immunol. 4, e35 (2015).","journal-title":"Clin. Trans. Immunol."},{"key":"e_1_3_2_35_2","unstructured":"WHO Cumulative Number of Confirmed Human Cases of Avian Influenza A\/(H5N1) Reported to WHO 2009 [cited 2009 12\/01\/09]. Available from: http:\/\/www.who.int\/csr\/disease\/avian_influenza\/country\/cases_table_2009_09 _24\/en\/."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/irv.12351","article-title":"A review of the changes to the licensing of influenza vaccines in Europe","volume":"10","author":"Wijnans L.","year":"2016","unstructured":"L. Wijnans, B. Voordouw, A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir. Viruses 10, 2\u20138 (2016).","journal-title":"Influenza Other Respir. Viruses"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.jid.2017.06.014","article-title":"Langerhans cells orchestrate TFH-dependent humoral immunity","volume":"137","author":"Vardam T.","year":"2017","unstructured":"T. Vardam, N. Anandasabapathy, Langerhans cells orchestrate TFH-dependent humoral immunity. J. Invest. Dermatol. 137, 1826\u20131828 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.04.016"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","article-title":"Enhanced humoral and type 1 cellular immune responses with Fluzone\u00ae adjuvanted with a synthetic TLR4 agonist formulated in an emulsion","volume":"27","author":"Baldwin S. L.","year":"2009","unstructured":"S. L. Baldwin, N. Shaverdian, Y. Goto, M. S. Duthie, V. S. Raman, T. Evers, F. Mompoint, T. S. Vedvick, S. Bertholet, R. N. Coler, S. G. Reed, Enhanced humoral and type 1 cellular immune responses with Fluzone\u00ae adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27, 5956\u20135963 (2009).","journal-title":"Vaccine"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv279"}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.aas9930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T18:57:57Z","timestamp":1704826677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.aas9930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,7]]}},"alternative-id":["10.1126\/sciadv.aas9930"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.aas9930","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,7]]},"article-number":"eaas9930"}}